INTENSITY THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
INTENSITY THERAPEUTICS, INC. (INTS) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-03-27
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $3.06M, a 79.70% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $15.05M.
- INTENSITY THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $3.06M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.06M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $3.06M 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $15.05M derived: sum of 2 quarters · filed 2025-03-13 | $15.05M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $8.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $8.84M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |